News
PMCB
0.7755
+4.63%
0.0343
Weekly Report: what happened at PMCB last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at PMCB last week (0126-0130)?
Weekly Report · 02/02 10:28
Weekly Report: what happened at PMCB last week (0119-0123)?
Weekly Report · 01/26 10:27
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/22 21:05
Weekly Report: what happened at PMCB last week (0112-0116)?
Weekly Report · 01/19 10:34
Weekly Report: what happened at PMCB last week (0105-0109)?
Weekly Report · 01/12 10:33
Thursday 1/8 Insider Buying Report: PMCB, COSM
NASDAQ · 01/08 18:36
Top PharmaCyte Insiders Quietly Boost Their Holdings in a Big Way
TipRanks · 01/08 02:03
PharmaCyte Biotech CEO Joshua Silverman Acquires Common Shares
Reuters · 01/07 22:44
Director Jonathan Schechter Acquires Common Shares of PharmaCyte Biotech Inc
Reuters · 01/07 22:43
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/05 21:05
Weekly Report: what happened at PMCB last week (1229-0102)?
Weekly Report · 01/05 10:27
Largest borrow rate increases among liquid names
TipRanks · 12/31/2025 13:45
Largest borrow rate increases among liquid names
TipRanks · 12/29/2025 13:45
Weekly Report: what happened at PMCB last week (1222-1226)?
Weekly Report · 12/29/2025 10:26
Weekly Report: what happened at PMCB last week (1215-1219)?
Weekly Report · 12/22/2025 10:26
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 12/19/2025 21:05
PharmaCyte Biotech Delays Quarterly Report Filing
TipRanks · 12/15/2025 22:17
PharmaCyte Biotech Delays Quarterly Financial Filing
Reuters · 12/15/2025 21:00
More
Webull provides a variety of real-time PMCB stock news. You can receive the latest news about Pharmacyte Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About PMCB
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.